Holen Sie sich die Stockscreener-App
1.03
3.47%
0.0345
Schlusskurs vom Vortag:
$0.9955
Offen:
$0.995
24-Stunden-Volumen:
322.41K
Relative Volume:
4.09
Marktkapitalisierung:
$4.43M
Einnahmen:
$79,300
Nettoeinkommen (Verlust:
$-6.92M
KGV:
-0.0543
EPS:
-18.9818
Netto-Cashflow:
$-5.34M
1W Leistung:
+11.96%
1M Leistung:
+28.51%
6M Leistung:
-51.64%
1J Leistung:
-6.36%
1-Tages-Spanne:
$0.99
$1.10
1-Wochen-Bereich:
$0.931
$1.14
52-Wochen-Spanne:
$0.7387
$8.9999
Virax Biolabs Group Ltd Stock (VRAX) Company Profile
Firmenname
Virax Biolabs Group Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie VRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRAX
Virax Biolabs Group Ltd
|
1.02 | 4.41M | 79,300 | -6.92M | -5.34M | -18.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.42 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.57 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.16 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
581.55 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Virax Biolabs Group Ltd Stock (VRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-31 | Eingeleitet | H.C. Wainwright | Buy |
Virax Biolabs Group Ltd Aktie (VRAX) Neueste Nachrichten
Technical Analysis: SPEL Semiconductor Limited (517166)Extraordinary performance - Autocar Professional
What analysts say about Allient Inc. stockGame-changing returns - jammulinksnews.com
AI for Trademark Infringement DetectionAlpha Stock Ideas - Newser
ICICI Prudential AMC Ltd (542631) Announces Strategic ShiftExceptional earning trajectories - jammulinksnews.com
What drives Virax Biolabs Group Limited stock priceAccelerated wealth building - Autocar Professional
Virax Biolabs Group Limited Stock Analysis and ForecastDynamic portfolio growth - jammulinksnews.com
Virax Biolabs receives Nasdaq minimum bid price deficiency notice - Investing.com Australia
Virax Biolabs receives Nasdaq minimum bid price deficiency notice By Investing.com - Investing.com India
Virax Biolabs Gets NASDAQ Deficiency Notice: What the 180-Day Compliance Timeline Means for Investors - Stock Titan
Is Virax Biolabs Group Limited a good long term investmentUnprecedented profits - jammulinksnews.com
How Virax Biolabs Group Limited stock performs during market volatilityFree Step-by-Step Investment Guide - Newser
Why ATCH stock attracts strong analyst attentionFree Consultation - Newser
Why Virax Biolabs Group Limited stock attracts strong analyst attentionFree Stock Portfolio Optimization - Newser
What makes Virax Biolabs Group Limited stock price move sharplyHigh Probability Setups - Newser
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Up 0.7% – Time to Buy? - Defense World
Virax Biolabs Group Full Year 2025 Earnings: Misses Expectations - simplywall.st
Virax Biolabs Announces CFO Resignation and Transition - TipRanks
FibroBiologics names new CFO after going public last year - The Business Journals
Kaival Brands Innovations Group (NASDAQ:KAVL) Trading Down 1.2% – Time to Sell? - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Up 2% – Here’s What Happened - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Trading Up 6.9% – Here’s What Happened - Defense World
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
FY2025 Earnings Estimate for VRAX Issued By HC Wainwright - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Coverage Initiated by Analysts at HC Wainwright - Defense World
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Yahoo Finance
Virax Biolabs Group Ltd.’s Innovative Diagnostics and Strategic Collaborations Justify Buy Rating - TipRanks
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update - Defense World
ELISpot and FluoroSpot Assay Market Size to Hit USD 576.59 Million by 2034 - Precedence Research
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 3.9% – What’s Next? - Defense World
Virax Biolabs Launches Clinical Study on T Cell Dysfunction - TipRanks
Virax Biolabs begins UK clinical study on T cell dysfunction - Investing.com India
Breakthrough T Cell Study: Virax Targets Long COVID and Chronic Fatigue Diagnosis Revolution - StockTitan
Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes - TipRanks
Virax Biolabs shares T-Cell dysfunction findings - Investing.com India
Virax Biolabs shares T-Cell dysfunction findings By Investing.com - Investing.com South Africa
Game-Changing Long COVID Diagnostic: Virax's New T-Cell Test Shows Promising Results - StockTitan
Virax Biolabs to Present at World Immune Regulation Meeting - TipRanks
Can Virax's T-Cell Research at WIRM 2025 Advance Post-Infection Syndrome Treatment? - StockTitan
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 205.8% in February - The AM Reporter
Cosmos Health expands distribution of Avian Influenza kits - MSN
Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Expands By 205.8% - Defense World
Virax Biolabs aligns with US vaccine transparency efforts By Investing.com - Investing.com South Africa
Virax Biolabs Aligns with US Health Department on Vaccine Transparency - TipRanks
How Virax's Vaccine Testing Tech Could Capitalize on New Government Transparency Push - StockTitan
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency - Benzinga
Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Market Watch: Virax Biolabs Group Ltd (VRAX)’s Noteworthy Drop, Closing at 1.71 - The Dwinnex
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 33.9% in January - Armenian Reporter
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait - Yahoo Finance
Finanzdaten der Virax Biolabs Group Ltd-Aktie (VRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.10%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):